• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Expert Opinion Hydroxyurea Could Prevent Strokes for People With Sickle Cell Disease in Lieu of Transfusions During COVID-19 Blood Supply Shortage

The COVID-19 pandemic threatens to cause a blood supply shortage in the United States, and as a result, clinicians may be compelled to ration or conserve blood products. For people living with sickle cell disease (SCD), blood transfusions are often necessary to decrease the frequency of severe symptoms.

In a new Blood paper, Michael R. DeBaun, MD, MPH, of Vanderbilt University Medical Center, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, suggests that while monthly blood transfusions are the standard method of stroke prevention for children with SCD and at high risk of strokes, initiation of hydroxyurea therapy may be an effective alternative, if the monthly blood transfusions are interrupted.



To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.